Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study
Hirokazu Kagawa(Jikei University School of Medicine), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Yushi Suhara(Jikei University School of Medicine), Jun Miki(Jikei University School of Medicine), Shun Saito(Jikei University School of Medicine), Takashi Kurauchi(Jikei University School of Medicine), Takafumi Yanagisawa(Jikei University School of Medicine), Yuji Yata(Jikei University School of Medicine), Keigo Sakanaka(Jikei University School of Medicine), Kojiro Tashiro(Jikei University School of Medicine), Sotaro Kayano(Jikei University Kashiwa hospital), Shunsuke Tsuzuki(Jikei University School of Medicine), Yu Imai(Jikei University School of Medicine), Ibuki Sadakane(Jikei University School of Medicine), Akira Furuta(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Koichi Aikawa(Jikei University School of Medicine), Minoru Nakazono(Jikei University School of Medicine), Shino Ajisaka(Jikei University School of Medicine), Kazuhiro Takahashi, Shiro Kurawaki(Jikei University School of Medicine), Kentaro Yoshihara(Jikei University School of Medicine), Yuma Goto(Jikei University School of Medicine), Hajime Onuma(Jikei University School of Medicine), R. Yamaguchi(Jikei University School of Medicine), Yuria Kiuchi(Jikei University School of Medicine), Keiichiro Miyajima(Jikei University School of Medicine), Kota Katsumi(Jikei University School of Medicine)
Cited by 10
Related Papers
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282
Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models
|Journal of Biological Chemistry|2004|212
Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel
|Journal of Biological Chemistry|2002|172